NMR-based Metabolomics in Alzheimer's Disease Research: a Review

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2023 Dec 15

PMID 38099198

Authors

Alessia Vignoli

Leonardo Tenori

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and represents the most common cause of dementia in the elderly population worldwide. Currently, there is no cure for AD, and the continuous increase in the number of susceptible individuals poses one of the most significant emerging threats to public health. However, the molecular pathways involved in the onset and progression of AD are not fully understood. This information is crucial for developing less invasive diagnostic instruments and discovering novel potential therapeutic targets. Metabolomics studies the complete ensemble of endogenous and exogenous metabolites present in biological specimens and may provide an interesting approach to identify alterations in multiple biochemical processes associated with AD onset and evolution. In this mini review, we summarize the results from metabolomic studies conducted using nuclear magnetic resonance (NMR) spectroscopy on human biological samples (blood derivatives, cerebrospinal fluid, urine, saliva, and tissues) from AD patients. We describe the metabolic alterations identified in AD patients compared to controls and to patients diagnosed with mild cognitive impairment (MCI). Moreover, we discuss the challenges and issues associated with the application of NMR-based metabolomics in the context of AD research.

Citing Articles

Studying Alzheimer's disease through an integrative serum metabolomic and lipoproteomic approach.

Vignoli A, Bellomo G, Paoletti F, Luchinat C, Tenori L, Parnetti L J Transl Med. 2025; 23(1):119.

PMID: 39871333 PMC: 11773822. DOI: 10.1186/s12967-025-06148-4.

Guidelines for the standardization of pre-analytical variables for salivary biomarker studies in Alzheimer's disease research: An updated review and consensus of the Salivary Biomarkers for Dementia Research Working Group.

Ng T, Udeh-Momoh C, Lim M, Gleerup H, Leifert W, Ajalo C Alzheimers Dement. 2024; 21(2):e14420.

PMID: 39737743 PMC: 11848381. DOI: 10.1002/alz.14420.

Lipid trajectories improve risk models for Alzheimer's disease and mild cognitive impairment.

Chase B, Frigerio R, Yucus C, Patel S, Maraganore D, Sanders A J Lipid Res. 2024; 66(1):100714.

PMID: 39586400 PMC: 11731482. DOI: 10.1016/j.jlr.2024.100714.

References

Wishart D . Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7):473-84. DOI: 10.1038/nrd.2016.32. View

Nicholson J, Lindon J . Systems biology: Metabonomics. Nature. 2008; 455(7216):1054-6. DOI: 10.1038/4551054a. View

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

Botello-Marabotto M, Martinez-Bisbal M, Calero M, Bernardos A, Pastor A, Medina M . Non-invasive biomarkers for mild cognitive impairment and Alzheimer's disease. Neurobiol Dis. 2023; 187:106312. DOI: 10.1016/j.nbd.2023.106312. View

Berezhnoy G, Laske C, Trautwein C . Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer's disease patients. Front Aging Neurosci. 2023; 15:1219718. PMC: 10483152. DOI: 10.3389/fnagi.2023.1219718. View

Kurbatova N, Garg M, Whiley L, Chekmeneva E, Jimenez B, Gomez-Romero M . Urinary metabolic phenotyping for Alzheimer's disease. Sci Rep. 2020; 10(1):21745. PMC: 7730184. DOI: 10.1038/s41598-020-78031-9. View

McCartney A, Vignoli A, Tenori L, Fornier M, Rossi L, Risi E . Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. NPJ Breast Cancer. 2019; 5:26. PMC: 6715716. DOI: 10.1038/s41523-019-0123-9. View

Emwas A, Roy R, McKay R, Tenori L, Saccenti E, Gowda G . NMR Spectroscopy for Metabolomics Research. Metabolites. 2019; 9(7). PMC: 6680826. DOI: 10.3390/metabo9070123. View

Foley S, Tansey K, Caseras X, Lancaster T, Bracht T, Parker G . Multimodal Brain Imaging Reveals Structural Differences in Alzheimer's Disease Polygenic Risk Carriers: A Study in Healthy Young Adults. Biol Psychiatry. 2016; 81(2):154-161. PMC: 5177726. DOI: 10.1016/j.biopsych.2016.02.033. View

10.

Vignoli A, Santini G, Tenori L, Macis G, Mores N, Macagno F . NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients. J Proteome Res. 2019; 19(1):64-74. DOI: 10.1021/acs.jproteome.9b00345. View

11.

Vignoli A, Meoni G, Ghini V, Di Cesare F, Tenori L, Luchinat C . NMR-Based Metabolomics to Evaluate Individual Response to Treatments. Handb Exp Pharmacol. 2022; 277:209-245. DOI: 10.1007/164_2022_618. View

12.

Vignoli A, Tenori L, Luchinat C, Saccenti E . Age and Sex Effects on Plasma Metabolite Association Networks in Healthy Subjects. J Proteome Res. 2017; 17(1):97-107. DOI: 10.1021/acs.jproteome.7b00404. View

13.

Gonzalez-Dominguez R, Sayago A, Fernandez-Recamales A . Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1071:75-92. DOI: 10.1016/j.jchromb.2017.02.008. View

14.

di Costanzo A, Paris D, Melck D, Angiolillo A, Corso G, Maniscalco M . Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features. Sci Rep. 2020; 10(1):15612. PMC: 7515866. DOI: 10.1038/s41598-020-71832-y. View

15.

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

16.

Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G . Can Alzheimer disease be a form of type 3 diabetes?. Rejuvenation Res. 2012; 15(2):217-21. DOI: 10.1089/rej.2011.1289. View

17.

Yilmaz A, Ustun I, Ugur Z, Akyol S, Hu W, Fiandaca M . A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning. J Alzheimers Dis. 2020; 78(4):1381-1392. DOI: 10.3233/JAD-200305. View

18.

Yilmaz A, Ugur Z, Bisgin H, Akyol S, Bahado-Singh R, Wilson G . Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment: A Pilot Study. Metabolites. 2020; 10(9). PMC: 7569858. DOI: 10.3390/metabo10090357. View

19.

Costanzo M, Caterino M, Sotgiu G, Ruoppolo M, Franconi F, Campesi I . Sex differences in the human metabolome. Biol Sex Differ. 2022; 13(1):30. PMC: 9199320. DOI: 10.1186/s13293-022-00440-4. View

20.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009; 302(4):385-93. DOI: 10.1001/jama.2009.1064. View